Table 5.
Frequency distribution of patients characterized by CA15.3 and CEA values above and below the relevant threshold before treatment at different time points.
| CA15.3 | CEA | ||||||
|---|---|---|---|---|---|---|---|
| Best response: PD (n=28) | Best response: PD (n=28) | ||||||
| PT | PD | n (%) | p value | PT | PD | n (%) | p value |
| <25 | <25 | 1 (3.57%) | 0.450 | ≤5 | ≤5 | 8 (28.57%) | 1 |
| <25 | ≥25 | 2 (7.14%) | ≤5 | >5 | 2 (7.14%) | ||
| ≥25 | <25 | 5 (17.86%) | >5 | ≤5 | 2 (7.14%) | ||
| ≥25 | ≥25 | 20 (71.43%) | >5 | >5 | 16 (57.14%) | ||
| Best response: CR/PR/SD ( n =47) | Best response: CR/PR/SD ( n =47) | ||||||
| BR | PD | n (%) | p value | BR | PD | n (%) | p value |
| <25 | <25 | 3 (6.25%) | 0.617 | ≤5 | ≤5 | 19 (40.43%) | 0.045* |
| <25 | ≥25 | 3 (6.25%) | ≤5 | >5 | 8 (17.02%) | ||
| ≥25 | <25 | 1 (2.08%) | >5 | ≤5 | 1 (2.13%) | ||
| ≥25 | ≥25 | 40 (85.42%) | >5 | >5 | 19 (40.43%) | ||
p values are derived from the McNemar test.
*
p<0.05.
BR, best response; PD, progressive disease; PT, pretreatment.